MediciNova Inc (MNOV) - Financial and Strategic SWOT Analysis Review

September 2021 | 49 pages | ID: MF5D8A19B10EN
GlobalData

Abstracts

MediciNova Inc (MNOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MediciNova Inc (MediciNova) is a biopharmaceutical company that focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurological, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and respiratory diseases. The company’s non-core programs formulations developed for indications include treatment of bronchial asthma; interstitial cystitis; solid tumors; and for the treatment of preterm labor. It has partnerships with various companies such as Angiogene Pharmaceuticals Ltd, Kyorin Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, and Meiji Seika Kaisha Ltd, to develop and commercialize its products. MediciNova is headquartered in La Jolla, California, the US.

MediciNova Inc Key Recent Developments

Aug 12,2021: MediciNova Reports Second Quarter 2021 Financial Results and Business Update
Jun 14,2021: MediciNova to Participate in Maxim Group Fireside Chat
May 13,2021: MediciNova Reports First Quarter 2021 Financial Results and Business Update
Apr 22,2021: MediciNova receives gene therapy milestone payments
Apr 19,2021: MediciNova to Participate in the B. Riley Neuroscience Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

MediciNova Inc - Key Facts
MediciNova Inc - Key Employees
MediciNova Inc - Key Employee Biographies
MediciNova Inc - Major Products and Services
MediciNova Inc - History
MediciNova Inc - Company Statement
MediciNova Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
MediciNova Inc - Business Description
MediciNova Inc - Corporate Strategy
MediciNova Inc - SWOT Analysis
SWOT Analysis - Overview
MediciNova Inc - Strengths
MediciNova Inc - Weaknesses
MediciNova Inc - Opportunities
MediciNova Inc - Threats
MediciNova Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MediciNova Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 12, 2021: MediciNova Reports Second Quarter 2021 Financial Results and Business Update
Jun 14, 2021: MediciNova to Participate in Maxim Group Fireside Chat
May 13, 2021: MediciNova Reports First Quarter 2021 Financial Results and Business Update
Apr 22, 2021: MediciNova receives gene therapy milestone payments
Apr 19, 2021: MediciNova to Participate in the B. Riley Neuroscience Conference
Apr 15, 2021: MediciNova to Participate in the UBS Global Healthcare Virtual Conference
Mar 08, 2021: MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
Oct 21, 2020: MediciNova appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair
Jul 27, 2020: MediciNova announces SARS-CoV-2 vaccine joint development with BioComo and Mie University Japan
Jun 19, 2020: MEDICINOVA: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

MediciNova Inc, Key Facts
MediciNova Inc, Key Employees
MediciNova Inc, Key Employee Biographies
MediciNova Inc, Major Products and Services
MediciNova Inc, History
MediciNova Inc, Subsidiaries
MediciNova Inc, Key Competitors
MediciNova Inc, Ratios based on current share price
MediciNova Inc, Annual Ratios
MediciNova Inc, Annual Ratios (Cont...1)
MediciNova Inc, Interim Ratios
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MediciNova Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

MediciNova Inc, Performance Chart (2016 - 2020)
MediciNova Inc, Ratio Charts
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MediciNova Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021